Subscribe
shutterstock_1960556293_molly_woodward
Molly Woodward / Shutterstock.com
21 October 2021Asia

Pfizer fights approval of generic Ibrance

Pfizer is seeking to block a generic version of its cancer drug Ibrance (palbociclib) from entering the market until the patent covering the drug expires in May 2036.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Pfizer sues India generic drugmaker over cancer drug
14 January 2021   Pharmaceutical company Pfizer has accused generic drug maker Aurobindo of infringement, as it attempts to block the roll-out of copies of its blockbuster arthritis drug, Xeljanz.
Generics
Delhi court approves Natco generic of Novartis cancer drug
29 August 2019   The Delhi High Court has cleared the way for a generic version of Novartis’ small-cell lung cancer drug Ceritinib, after the Swiss pharmaceutical company’s patent was revoked.
Big Pharma
Pfizer sued over COVID-19 antiviral drug
28 June 2022   Pfizer is facing a lawsuit centring on its COVID-19 antiviral, Paxlovid, after Enanta Pharmaceuticals filed a complaint citing patent infringement.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Big Pharma
Pfizer sues India generic drugmaker over cancer drug
14 January 2021   Pharmaceutical company Pfizer has accused generic drug maker Aurobindo of infringement, as it attempts to block the roll-out of copies of its blockbuster arthritis drug, Xeljanz.
Generics
Delhi court approves Natco generic of Novartis cancer drug
29 August 2019   The Delhi High Court has cleared the way for a generic version of Novartis’ small-cell lung cancer drug Ceritinib, after the Swiss pharmaceutical company’s patent was revoked.
Big Pharma
Pfizer sued over COVID-19 antiviral drug
28 June 2022   Pfizer is facing a lawsuit centring on its COVID-19 antiviral, Paxlovid, after Enanta Pharmaceuticals filed a complaint citing patent infringement.

More on this story

Big Pharma
Pfizer sues India generic drugmaker over cancer drug
14 January 2021   Pharmaceutical company Pfizer has accused generic drug maker Aurobindo of infringement, as it attempts to block the roll-out of copies of its blockbuster arthritis drug, Xeljanz.
Generics
Delhi court approves Natco generic of Novartis cancer drug
29 August 2019   The Delhi High Court has cleared the way for a generic version of Novartis’ small-cell lung cancer drug Ceritinib, after the Swiss pharmaceutical company’s patent was revoked.
Big Pharma
Pfizer sued over COVID-19 antiviral drug
28 June 2022   Pfizer is facing a lawsuit centring on its COVID-19 antiviral, Paxlovid, after Enanta Pharmaceuticals filed a complaint citing patent infringement.

More features

President Trump 2.0: Five major areas to watch
China’s new policies on foreign investment in healthcare and biotech
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug